Rheumatic immune-related adverse events of checkpoint therapy for cancer
BMJ GroupEpisode Description
More Episodes
-
0Promoting gender equity in academic rheumatology
-
0Autoantibodies against PTM proteins as biomarkers for lupus
-
0Balancing risks with JAK inhibitors in RMDs after the ORAL Surveillance study
-
0Air pollution associated with higher risk of developing autoimmune diseases
-
0COVID-19 and cytokines - same storm, different origins?
-
0Imaging in large vessel vasculitis
-
0The use of MRI in rheumatology
-
0Improving the peer review skills of young researchers in rheumatology
-
0Don’t neglect nutrition in rheumatoid arthritis!
-
0A standardised catalogue of patient scenarios to improve the ranking of RA disease activity?
-
0Osteoarthritis or rheumatoid? The MDHAQ patient questionnaire role in routine rheumatology care
-
0Sjögren’s syndrome: what do we know so far?
-
0Branded drug or biosimilar? Reasons to adopt generics in rheumatology, by Professor Jonathan Kay
-
0Early diagnosis and treatment: the Rheumatic Diseases Portuguese Register
-
0Interleukin-17: a role in inflammatory arthritis and implication for clinical practice
-
0Welcome to RMD Open
Comments (0)
0/500
New Comments(0)
What do you think of this episode?